Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

6 months ago Solid tumor

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

mRNA Vaccine

Tumor immunotherapy, as an emerging method for diagnosing and treating tumors, has garnered widespread attention since its inception. Prior to the advent of tumor immunotherapy, the clinical treatment of solid tumors relied solely on traditional surgical removal, radiotherapy, and chemotherapy. Although these methods were effective, they came with significant drawbacks such as drug side effects and the risk of recurrence.

Since the 1990s, mRNA vaccines have been considered therapeutic vaccines. During the COVID-19 pandemic in 2020, mRNA vaccines were used in clinical treatments, saving countless lives. Today, as the advantages of mRNA vaccines are gradually being discovered, they are now applied in multiple fields.

The advent of China’s first self-replicating mRNA vaccine JCXH-211 undoubtedly marks a new breakthrough in the clinical diagnosis and treatment of various solid tumors in China.

What is the mRNA Vaccine JCXH-211?

JCXH-211 is the world’s first self-replicating RNA drug encoding human interleukin-12 (IL-12) to enter clinical trials. This srRNA vaccine delivers mRNA encoding IL-12 into the cytoplasm, continuously expressing IL-12 to enhance the body’s immune response against tumor cells.

In preclinical studies involving various mouse and PDX disease models, JCXH-211 has shown the ability to effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. Comprehensive GLP toxicology studies have also demonstrated good safety.

JCXH-211 has a broad range of indications and is expected to effectively treat multiple solid tumors. The anticipated prospects are as follows:

1. Lung Cancer:

As one of the leading causes of cancer death worldwide, lung cancer is often diagnosed at a late stage due to difficulties in early detection. JCXH-211, through continuous expression of IL-12 and activation of immune cells, is expected to effectively control the growth and spread of lung cancer cells.

2. Colorectal Cancer:

Current clinical treatments for colorectal cancer primarily involve surgery and radiotherapy/chemotherapy, which can remove visible tumors but have a high recurrence rate. Periodic administration of JCXH-211 may significantly reduce recurrence and improve patient survival.

3. Soft Tissue/Chondrosarcoma:

These tumors are highly invasive and cover a wide range of areas, often affecting surrounding soft tissues and progressing rapidly. Current treatments are limited to surgery and radiotherapy/chemotherapy, which, although somewhat effective, are not thorough, leading to high recurrence rates. JCXH-211 could become a new treatment method, enhancing the body’s immune response to combat these stubborn cancer cells.

4. Skin Cancer:

Clinical treatments for skin cancer mainly include surgery and radiotherapy. While most skin cancers have a good prognosis, the effects on intractable melanoma are poor. The expression of IL-12 can activate specific T cells, greatly aiding in the elimination of melanoma cells.

High-Efficiency Activation and Safety of the mRNA Vaccine JCXH-211!

mRNA vaccines not only encode antigens to induce specific immune responses against tumors but also possess inherent immunostimulatory properties. This dual mechanism allows JCXH-211 to activate the immune system more efficiently, enhancing the overall anti-tumor effect.

Moreover, the safety of mRNA vaccines is well-recognized. Since DNA is the genetic material of most species, including humans and viruses, and is transcribed into mRNA before being translated into proteins to perform functions in the body, injecting mRNA into the human body does not enter the cell nucleus, thereby eliminating the risk of genomic insertion mutations. Additionally, mRNA can be naturally degraded and excreted from the body, preventing accumulation. Thus, JCXH-211 presents lower potential risks and is safer.

Currently, clinical trials are progressing steadily. With the rapid advancement of tumor immunotherapy, JCXH-211 is expected to become a standard treatment for various solid tumors, offering hope to many cancer patients.

To assess whether the condition is suitable for cancer vaccine or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

6 months ago Solid tumor

Tumors Vanish After One Year of Treatment! The First Advanced Gastric Cancer Patient to Receive the New Cancer Vaccine Achieves Lasting Remission

Tumors Vanish After One Year of Treatment! The First Advanced #GastricCancer Patient to Receive the New #Cancer Vaccine Achieves Lasting Remission

Cancer Vaccine

Mrs. Liu, who was battling advanced gastric cancer, never imagined that one year ago, she was on the brink of death due to chemotherapy, with her disease progressing rapidly and cancer spreading throughout her body… Later, she won the “lottery” of her life. She received one of the world’s most advanced immunotherapies—cancer vaccines—in Fujian. One year later, all her cancer lesions have completely disappeared! Her successful case was even published in a prominent international journal, a Nature sub-journal, causing a huge sensation.

First Advanced Gastric Cancer Patient to Receive the New Cancer Vaccine Achieves Lasting Remission! Tumors Vanish After One Year of Treatment

In July 2017, 66-year-old Mrs. Liu was unfortunately diagnosed with stage IV gastric cancer. After surgery, she underwent FOLFOX chemotherapy to eliminate residual cancer cells, and everything seemed to be going well. Unfortunately, just eight months later, Mrs. Liu’s cancer recurred, and multiple lesions were found not only in her stomach but also in her peritoneum and lymph nodes, indicating that the cancer had rapidly spread throughout her body. Mrs. Liu had to undergo chemotherapy again. However, this time, her body could no longer withstand the side effects. After two cycles of Nab-paclitaxel, she was on the brink of death due to severe side effects and had to stop chemotherapy.

When she and her family were in despair, the doctors brought them good news. A nationally renowned cancer center was conducting a clinical trial of a cancer vaccine. Remarkably, this new type of cancer vaccine was a hot topic of research worldwide and had achieved significant breakthroughs.

The new cancer vaccine is a personalized, neoantigen-loaded monocyte-derived dendritic cell vaccine, known as Neo-MoDC. This vaccine fully mobilizes the immune system: dendritic cells (DCs) recognize cancer antigens, present antigens to activate T cells, promote T cell enrichment, and mobilize T cells to eliminate cancer cells, ultimately launching a series of precise and powerful attacks on cancer cells throughout the body.

Mrs. Liu decided to participate in the clinical trial of this new therapy.

This new therapy is actually much more complex than described above. Doctors first performed whole-exome sequencing on her tumor tissue samples, identifying 1,096 somatic non-synonymous mutations. They then determined her HLA (human leukocyte antigen) types as HLA-A02:07, HLA-A24:02, HLA-B40:01, HLA-B46:01, HLA-C01:02, and HLA-C03:04. Based on the binding affinity of these predicted mutant peptides with the patient’s HLA I class alleles, eight soluble mutant epitopes with the highest affinity were identified to prepare a personalized neoantigen dendritic cell cancer vaccine specifically targeting her cancer cells.

Mrs. Liu successfully received two months of subcutaneous Neo-MoDC vaccine injections to activate the T cell anti-tumor immune response. Researchers confirmed that the Neo-MoDC vaccine successfully induced a neoantigen-specific T cell response. For better therapeutic results, from day 65, Mrs. Liu received nivolumab (PD-1) treatment every 14 days.

An unexpected surprise occurred.

Five days later, Mrs. Liu’s CA-125 level rapidly dropped from 596 to 64 U/ml;

Two weeks later, malignant ascites disappeared, and clinical imaging showed a 30% reduction in the volume of metastatic supraclavicular lymph nodes;

Two months later, all metastatic lymph nodes reduced to less than 1 cm, and evaluations showed complete remission (CR) in the lymph nodes, with a 20% reduction in the longest diameter of ovarian metastatic lesions.

On the 231st day after the initial vaccination, imaging showed complete regression of all lesions;

On the 389th day of combined treatment, a CT scan showed that the ovarian metastatic lesions had also completely disappeared;

Subsequent CT scans confirmed that by the time of the paper’s publication (October 2021), complete regression had lasted for over 25 months.

This result indicates that the neoantigen vaccine Neo-MoDC and PD-1 in combination therapy may enhance each other’s efficacy, achieving better treatment outcomes, and providing a new immunotherapy combination for metastatic gastric cancer and other tumor types.

Mrs. Liu said that after the failure of chemotherapy, she was in despair, counting down the days of her life. She couldn’t imagine that she would have the opportunity to receive such cutting-edge therapy in China, let alone believe that she would become the fortunate one in this milestone research, successfully defeating cancer and returning to normal life!

In June 2022, this study was published in a prominent international journal, a Nature sub-journal, marking the first known case of complete and lasting tumor regression in gastric cancer through neoantigen-based DC vaccine and PD-1 therapy, which is of milestone significance!

Cancer Vaccines Will Ultimately Become a Sword Against Cancer!

Throughout the long history of humanity, various vaccines have been developed to combat devastating diseases, leading to the eradication of deadly diseases like smallpox and poliomyelitis. Similarly, the medical community is actively developing various vaccines to fight cancer, hoping to awaken our immune system to recognize and kill cancer cells upon injection, and to generate immune memory responses that protect us continuously, attacking any emerging cancer cells before they form tumors. This vision will eventually become a reality!

Immunotherapy is hailed as the hope for conquering cancer. Whether it’s the currently approved PD-1 immune checkpoint inhibitor therapy for various cancers, adoptive cell immunotherapy represented by CAR-T, or numerous cancer vaccines under development, they represent just the tip of the iceberg in immunology. Researchers are uncovering more information from this iceberg, learning how to control immune responses, and using these therapeutic approaches in clinical practice to benefit patients, giving us increasing hope for survival. The hope for conquering cancer may lie within these advances. We look forward to more breakthroughs in immunotherapy, bringing more miracles to cancer patients.

To assess whether the condition is suitable for New Cancer Vaccine or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#CancerVaccine #StomachCancer #Immunotherapy #CancerResearch #MedicalBreakthrough #CancerTreatment #HealthcareInnovation #PatientSuccess #Oncology #MedicalAdvancements

6 months ago Solid tumor

Breakthrough in mRNA Cancer Vaccine! Chinese Medical Team Brings New Hope to Advanced Cancer Patients Resistant to Traditional Treatments

Cancer Vaccine

The rise of mRNA vaccines during the COVID-19 pandemic has inspired their use in cancer treatment. Recently, Professor Shen Baiyong’s team at Ruijin Hospital published a groundbreaking study in Cell Research. They reported the first therapeutic effects of an mRNA cancer vaccine targeting the KRAS G12V mutation in solid tumors globally, offering new hope to advanced cancer patients resistant to traditional treatments.

#### Research Highlights

Two patients with the KRAS G12V mutation and HLA-A*11:01 positivity were treated with the KRAS G12V mRNA vaccine and PD-1 inhibitors.

– First Case: An 86-year-old woman with pancreatic cancer showed significant lesion reduction and improved quality of life after treatment.

– Second Case: A 69-year-old man with advanced lung cancer experienced partial tumor regression and no notable side effects after treatment.

#### Significance

This study highlights the efficacy of mRNA cancer vaccines in treating advanced solid tumors. The KRAS G12V mutation has strong binding affinity with HLA-A11:01, common in Asians, suggesting many could benefit from this therapy.

Professor Shen, who leads the Pancreatic Disease Treatment Center at Ruijin Hospital, focuses on comprehensive pancreatic cancer care and has initiated clinical trials on mRNA vaccines for advanced patients.

#### Clinical Trials

Ruijin Hospital is conducting trials on fixed single-target, multi-target personalized, and postoperative preventive mRNA vaccines, promising new hope for patients. For more information, please contact us.

This innovative research could bring new treatment options to more patients worldwide.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CancerResearch #mRNAVaccine #MedicalBreakthrough #AdvancedCancer #InnovativeTreatment #Healthcare #Oncology #ChineseMedicalTeam #NewHope #CancerTreatment #CellResearch

9 months ago CAR-T

🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉

Advanced Science

Say hello to the future of cancer treatment! A groundbreaking mRNA cancer vaccine jointly developed by Chinese scientists has hit the spotlight, promising to elevate tumor suppression rates and extend survival periods.

🔬 What’s the Buzz? 🔬
Published in the prestigious journal “Advanced Science”, the research titled “All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer” reveals a novel mRNA cancer vaccine. This vaccine, packaged with lipid nanoparticles (LNPs), delivers All-Trans-Retinoic Acid (ATRA) and mRNA, effectively stimulating mucosal immune responses in the intestines. Compared to conventional mRNA-LNP vaccines, this innovative approach significantly boosts tumor suppression and prolongs survival rates.

🩺 Why It Matters 🩺
Colorectal cancer ranks third in cancer incidence and second in mortality globally. Conventional treatments such as surgery, chemotherapy, and radiation often come with high recurrence rates. Enter cancer immunotherapy—the beacon of hope in the fight against colorectal cancer. Cancer vaccines, a vital component of immunotherapy, harness the body’s immune system to target and destroy cancer cells. With the recent success of mRNA vaccines for COVID-19, mRNA cancer vaccines have garnered immense attention for their potential to revolutionize cancer treatment.

🚀 The Breakthrough 🚀
The key lies in ATRA-LNP’s ability to induce cytotoxic T cells in the intestines, offering a promising therapeutic approach for colorectal cancer. In animal models, ATRA-LNP treatment led to a remarkable reduction in tumor growth and extended survival rates compared to conventional treatments. These findings underscore the potential of mRNA cancer vaccines, particularly in enhancing the treatment outcomes for colorectal cancer patients.

🌟 The Takeaway 🌟
With its ability to activate anti-tumor immune responses at mucosal surfaces, the novel mRNA cancer vaccine brings hope for improved outcomes in colorectal cancer treatment. ATRA incorporation into LNPs not only enhances mRNA delivery efficiency but also directs activated T cells towards the intestines, amplifying their anti-tumor effects. This study paves the way for a promising future in enhancing the efficacy of mRNA cancer vaccines against colorectal cancer.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: 137 1795 9070

#CancerResearch #MedicalBreakthrough #ImmunotherapyInAction #ColorectalCancerFighters #mRNA #CancerVaccine #vaccine #colorectal #colorectalcancer #cancerfighters #chinesemedical #cancertreatment #tumor

Menu

Tags Archives: Cancer Vaccine

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~